Efficacy and Safety of Hyaluronic Acid Injection on Symptoms of Vulvovaginal Atrophy in Postmenopausal Women

NACompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

January 21, 2020

Primary Completion Date

September 29, 2021

Study Completion Date

June 18, 2022

Conditions
Vulvovaginal Atrophy
Interventions
DEVICE

Injection of DESIRIAL®

"DESIRIAL® is a hyaluronic acid injectable gel intended to treat symptoms associated with vulvovaginal atrophy in postmenopausal women by vaginal mucosa rehydration in this study.~1 mL of DESIRIAL® will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."

OTHER

Injection of placebo

"Placebo is an isotonic saline solution (0.9% NaCl).~1 mL of placebo will be injected in the vestibule and on the posterior and lateral walls of the vagina, 2 to 3 cm after the introitus."

Trial Locations (14)

1300

Cabinet Dr Ali Bennani, Wavre

1860

Gynaecologie Dr Deniz Gulcan, Meise

1930

MIRHA, Zaventem

2018

Gynecology private office, Antwerp

2800

Gynaecologisch Centrum, Mechelen

4000

Cabinet Gynécologie Obstétrique, Liège

13008

Cabinet de gynécologie, Marseille

31000

Cabinet de gynécologie, Toulouse

33300

Clinique Georges V, Bordeaux

40220

Cabinet de Gynécologie, Tarnos

44800

Polyclinique de l'Atlantique, Saint-Herblain

59037

CHRU Jeanne de Flandres, Lille

66000

Cabinet de gynécologie, Perpignan

75016

Cabinet de Gynécologie, Paris

Sponsors
All Listed Sponsors
lead

Laboratoires Vivacy

INDUSTRY